On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCL

Target Audience
This activity has been designed for oncology clinicians and others who may also have an interest in this topic, specifically those focused on lung and/or breast cancer.

Program Overview
Although treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing, these diseases remain incurable. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. This infographic provides an overview of HER3-targeted ADCs, including expert commentary from oncology clinicians, to ensure healthcare professionals are up to date regarding advances in treatments for NSCLC and breast cancer.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Describe the rationale for targeting HER3 in solid tumors, particularly epidermal growth factor receptor (EGFR)-mutated NSCLCs and HER3-expressing breast cancers
Summarize the latest data from ongoing clinical trials of ADCs that target HER3 for the treatment of advanced solid tumors